Nivolumab Plus Ipilimumab Should Be the Standard of Care for First-Line Unresectable Epithelioid Mesothelioma

Author(s):: Baas, P. (0000-0001-7018-9556)

Published: 2021
Publication type: Other

Date issued: 2021-12-17
Language: English
Publisher: ELSEVIER SCIENCE INC
hdl: 1887/3565035
doi: 10.1016/j.jtho.2021.07.029